Remove Development Remove Drug Delivery Remove Insulin Remove Medicine
article thumbnail

Injectable Drug Delivery 2022

pharmaphorum

There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.

article thumbnail

Patient Centricity in Insulin Delivery: Improving the Injection Experience with Droplet Micron

XTalks

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea On 14th, MEDICOX, listed on KOSDAQ, signed an exclusive distribution contract with an oral drug delivery platform developer, ORAMED Pharmaceuticals on the oral insulin license. EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent ?-thalassemia EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it had completed the last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent ?-thalassemia. Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 Regulatory News: Lysogene announced that it will h

BioSpace

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

article thumbnail

Rising Need of Autoinjectors

Roots Analysis

Further, in order to improve the quality of life in these patients, companies have developed novel devices capable of delivering a variety of formulations of different drugs / therapies, in an efficient and relatively simple manner. Autoinjector As Emerging Drug Delivery Device.

article thumbnail

The Future of Drug Delivery: Exploring Large Volume Wearable Injectors

Roots Analysis

Therefore, medical technology is rapidly evolving, enabling more advanced and patient-friendly methods of drug delivery. In the pursuit of creating patient-centric healthcare solutions, the medical industry has witnessed a groundbreaking advancement in drug delivery with the emergence of large volume wearable injectors.